Spirooxindoles: Promising scaffolds for anticancer agents B Yu, DQ Yu, HM Liu European Journal of Medicinal Chemistry 97, 673-698, 2015 | 777 | 2015 |
LSD1/KDM1A inhibitors in clinical trials: Advances and prospects Y Fang, G Liao*, B Yu* Journal of Hematology & Oncology 12 (1), 129, 2019 | 328 | 2019 |
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy K Tang, Y Wu, Y Song, B Yu* Journal of Hematology & Oncology 14, 68, 2021 | 203 | 2021 |
Discovery of orally active anticancer candidate CFI-400945 derived from biologically promising spirooxindoles: Success and challenges B Yu, Z Yu, PP Qi, DQ Yu, HM Liu European Journal of Medicinal Chemistry 95, 35-40, 2015 | 159 | 2015 |
Synthesis and biological evaluation of novel steroidal [17, 16-d][1, 2, 4] triazolo [1, 5-a] pyrimidines LH Huang, YF Zheng, YZ Lu, CJ Song, YG Wang, B Yu, HM Liu Steroids 77 (6), 710-715, 2012 | 133 | 2012 |
Targeting BRD4 for Cancer therapy: Inhibitors and Degraders Y Duan, Y Guan, W Qin, X Zhai, B Yu*, HM Liu* MedChemComm 9, 1779-1802, 2018 | 130 | 2018 |
Natural product-derived spirooxindole fragments serve as privileged substructures for discovery of new anticancer agents B Yu, YC Zheng, XJ Shi, PP Qi, HM Liu Anti-Cancer Agents in Medicinal Chemistry 16 (10), 1315-1324, 2016 | 120 | 2016 |
Advances toward LSD1 inhibitors for cancer therapy X Fu, P Zhang, B Yu Future Medicinal Chemistry 9 (11), 1227-1242, 2017 | 119 | 2017 |
Cancer nanotechnology: Enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapy Y Sun, W Ma, Y Yang, M He, A Li, L Bai, B Yu, Z Yu Asian Journal of Pharmaceutical Sciences 14 (6), 581-594, 2019 | 106 | 2019 |
Irreversible LSD1 inhibitors: application of tranylcypromine and its derivatives in cancer treatment Y C Zheng, B Yu, G Z Jiang, X J Feng, P X He, X Y Chu, W Zhao, H M Liu Current topics in medicinal chemistry 16 (19), 2179-2188, 2016 | 99 | 2016 |
Synthesis and biological evaluation of coumarin–1, 2, 3-triazole–dithiocarbamate hybrids as potent LSD1 inhibitors XW Ye, YC Zheng, YC Duan, MM Wang, B Yu, JL Ren, JL Ma, E Zhang, ... MedChemComm 5 (5), 650-654, 2014 | 94 | 2014 |
A Cell Membrane‐Targeting Self‐Delivery Chimeric Peptide for Enhanced Photodynamic Therapy and In Situ Therapeutic Feedback W Ma, SN Sha, PL Chen, M Yu, JJ Chen, CB Huang, B Yu, Y Liu, LH Liu*, ... Advanced Healthcare Materials, 1901100, 2019 | 92 | 2019 |
Recent Progress in Histone Methyltransferase (G9a) Inhibitors as Anticancer Agents H Cao, L Li, D Yang, L Zeng, Y Xie, B Yu*, G Liao*, J Chen* European Journal of Medicinal Chemistry 179, 537-546, 2019 | 87 | 2019 |
The Development of Biologically Important Spirooxindoles as New Antimicrobial Agents YT Yang, JF Zhu, G Liao, HJ Xu*, B Yu* Current Medicinal Chemistry 25 (19), 2233-2244, 2018 | 87 | 2018 |
Natural products as LSD1 inhibitors for cancer therapy Y Fang, C Yang, Z Yu, X Li, Q Mu*, G Liao*, B Yu* Acta Pharmaceutica Sinica B 11 (3), 621-631, 2021 | 86 | 2021 |
FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: synthesis and clinical application S Wang, XH Yuan, SQ Wang, W Zhao, XB Chen, B Yu* European Journal of Medicinal Chemistry 214, 113218, 2021 | 82 | 2021 |
Efficient synthesis of new antiproliferative steroidal hybrids using the molecular hybridization approach B Yu, PP Qi, XJ Shi, R Huang, H Guo, YC Zheng, DQ Yu, HM Liu European Journal of Medicinal Chemistry 117, 241-255, 2016 | 79 | 2016 |
TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy YC Zheng, B Yu, ZS Chen, Y Liu, HM Liu Epigenomics 8 (5), 651-666, 2016 | 79 | 2016 |
Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives Y Fang, G Liao*, B Yu* Acta Pharmaceutica Sinica B 10, 1253-1278, 2020 | 77 | 2020 |
A novel [1, 2, 4] triazolo [1, 5- a] pyrimidine-based phenyl-linked steroid dimer: Synthesis and its cytotoxic activity B Yu, XJ Shi, YF Zheng, Y Fang, E Zhang, DQ Yu, HM Liu European Journal of Medicinal Chemistry 69, 323-330, 2013 | 77 | 2013 |